Published 1 day ago • loading... • Updated 19 hours ago

Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death - Sarepta Therapeutics (NASDAQ:SRPT), Roche Holding (OTC:RHHBY)

Summary by Benzinga

In March, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy. The company reported a patient death following treatment with Elevidys, having suffered acute liver failure. Acute liver injury is a known possible side effect of Elevidys and other AAV-mediated gene therapies and is highlighted in the prescribing informa…

9 Articles

All

Left

Center

Right

Benzinga

Center

Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death - Sarepta Therapeutics (NASDAQ:SRPT), Roche Holding (OTC:RHHBY)

19 hours ago·New York, United States

Read Full Article

Investor's Business Daily

Right

Sarepta Dives On 'Another Unfortunate Development' For Its Gene Therapy

Sarepta stock tumbled Thursday after European officials put all studies of the company's gene therapy, Elevidys, on hold. The post Sarepta Dives On 'Another Unfortunate Development' For Its Gene Therapy appeared first on Investor's Business Daily.

24 hours ago

Read Full Article

biopharmadive.com

Center

Roche halts testing of Sarepta Duchenne gene therapy in Europe

The Swiss drugmaker, which holds European rights to Elevidys, suspended three trials while researchers investigate the death of a young man who died following treatment.

1 day ago

Read Full Article

Managed Healthcare Executive

Caregiver Burden and Value Assessments in Duchenne Muscular Dystrophy

Doing more to incorporate caregiver burden into value assessments and cost-effectiveness research of Duchene muscular dystrophy treatments was the focus of a recent International Society for Pharmacoeconomics and Outcomes Research (ISPOR) webinar.

22 hours ago

Read Full Article

neurologylive.com

Sarepta’s Duchenne Gene Therapy Trials Paused in Europe Amid Patient Death Investigation

The European Medicines Agency has requested a pause on 3 clinical trials of FDA-approved gene therapy Elevidys following the death of a patient who suffered acute liver failure after treatment.

22 hours ago

Read Full Article

Plato. Vertical Search. Ai. | PlatoAiStream. Data Intelligence. Vertical Search. Ai.

Roche Halts Testing Of Sarepta Duchenne Gene Therapy In Europe

Dive Brief: Roche has stopped enrolling and treating patients in three studies of the gene therapy Elevidys following the death of a 16-year-old patient with Duchenne muscular dystrophy. The European Medicines Agency asked for the temporary clinical hold until researchers and regulators finish an analysis into the young man’s cause of death, Roche said in a letter to the patient community this week. Sarepta Therapeutics, which developed the the…

23 hours ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year